Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
120 participants
INTERVENTIONAL
2008-01-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Lidcombe Program is a behavioral therapy program for preschool children designed to treat stuttering at its early stages. The treatment approach involves the direct participation of parents, who are trained during parent and child weekly visits to a speech language pathologist. In the first stage of the program, the clinician demonstrates the therapy to the parent, observes the parent conduct therapy and provides feedback and goals for the following week until the next clinic visit. The clinician guides the parent to provide three types of verbal "reinforcement" contingencies for the child's stutter free speech. These include, acknowledgment, praise and request for self-evaluation, where the child is asked to recognize his or her stutter free speech. If unambiguous stuttering occurs, the parent provides two types of verbal "punishment" contingencies including acknowledgment of the stuttering and request for self-correction, where the child is asked to repeat the stuttered word again. These contingencies are administered by parents in everyday speaking conversations, in order to promote generalization of fluent speech. When the child's stuttering is reduced to near-zero levels, the child then enters the second stage of the program, where the number of clinic visits are gradually phased out from bi-monthly to monthly to every 2 months, and so on, as required by the child. The purpose of the stage 2 visits is for the speech language pathologist to evaluate the child's speech and to ensure that near-zero stuttering levels are maintained.
When the first stage of the Lidcombe program is followed as the program was originally designed, the median treatment time to achieve the criteria of near-zero levels of stuttering is 11 one-hour weekly clinic visits, with treatment times varying according to the severity of the stuttering. However, clinicians have been deviating from the standard weekly sessions for various reasons. For instance, some private practitioners are offering first stage treatment visits once every 2 weeks rather than weekly and other practitioners are offering treatment intensively, so that clients from remote areas can have access to the Lidcombe program. As yet, there are no data to confirm whether treatment using fortnightly or twice weekly clinic visits is as effective or efficient as the standard weekly visits. The aim of this project is to evaluate the following questions: (1) Does altering the spacing of LP clinic visits affect treatment efficiency? (2) Does altering the spacing of LP clinic visits affect treatment efficacy?
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
The child will receive the Lidcombe Program 2x per week
The Lidcombe Program for early stuttering
2
The child will receive the Lidcombe Program once every 2 weeks (fortnightly visits)
The Lidcombe Program for early stuttering
3
The child will receive the standard Lidcombe Program once per week (control)
The Lidcombe Program for early stuttering
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The Lidcombe Program for early stuttering
The Lidcombe Program for early stuttering
The Lidcombe Program for early stuttering
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Stuttering for longer than 6 months
3. Functional English spoken by parent and child
4. Stuttering over 2%SS in one Beyond Clinic measure
5. Diagnosis of stuttering
Exclusion Criteria
2. Previous treatment for stuttering in last 6 months
3. Parental report of ADHD or intellectual disability
3 Years
6 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Health and Medical Research Council, Australia
OTHER
Newcastle University
OTHER
University of Sydney
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Australian Stuttering Research Centre, The University of Sydney
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Onslow
Role: PRINCIPAL_INVESTIGATOR
University of Sydney
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Newcastle
Newcastle, New South Wales, Australia
The Montreal Fluency Centre
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sally Hewat
Role: primary
Sarita Koushik
Role: backup
Rosalee Shenker
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
402763
Identifier Type: -
Identifier Source: secondary_id
402763-17
Identifier Type: -
Identifier Source: org_study_id